Related Experiment Videos
Serum iron, glutamic oxalacetic transaminase and creatine phosphokinase in acute myocardial infarction. A comparative
H A Hedayati1, A M Handjani, S Toussi
1Medical Department Pahlavi University Medical Center, Nemazee Hospital, Shiraz, Iran.
Insights
Serum iron levels decrease in the initial days after acute myocardial infarction. This finding may help detect heart attacks, complementing creatine phosphokinase and glutamic oxalacetic transaminase tests.
Area of Science:
- Cardiology
- Biochemistry
Background:
- Acute myocardial infarction (AMI) diagnosis relies on specific biomarkers.
- Established biomarkers include creatine phosphokinase (CPK) and serum glutamic oxalacetic transaminase (SGOT).
- Limitations exist in the sensitivity and specificity of current diagnostic markers.
Purpose of the Study:
- To investigate the diagnostic utility of serum iron levels in patients with acute myocardial infarction.
- To compare the sensitivity of serum iron measurements with CPK and SGOT assays in early AMI detection.
Main Methods:
- Serum iron levels were measured in thirty patients diagnosed with acute myocardial infarction.
- Measurements were taken during the first three days post-infarction.
- Serum iron results were compared with concurrent CPK and SGOT activity measurements.
Main Results:
- Subnormal serum iron concentrations were observed in all thirty patients within the first three days.
- The incidence of subnormal serum iron was higher than abnormalities detected by CPK and SGOT assays.
- Some patients exhibited abnormal serum iron with normal CPK levels, suggesting potential diagnostic value.
Conclusions:
- Serum iron determination is a sensitive indicator in the early phase of acute myocardial infarction.
- Serum iron measurements can supplement CPK and SGOT assays for improved AMI detection.
- Monitoring serum iron may enhance the diagnostic accuracy for acute myocardial infarction.
Abstract:
The serum iron was subnormal on the first three days, following acute myocardial infarction in thirty patients. This is significantly less than the incidence of abnormalities demonstrated by assays of creatine phosphokinase (CPK) and glutamic oxalacetic transaminase (SGOT) in serum. Occasional patients had abnormal serum iron concentrations in association with normal CPK activities. For this reason serum iron determination may usefully supplement CPK activity measurements and possibly those of SGOT activity as an aid to the detection of acute myocardial infarction.